[Oral administration of "Infectvac" for prevention of acute respiratory tract infections].
The efficacy of a newly developed polyvalent bacterial lysat vaccine "Infectvac" was tested in experimental studies in animals. It was shown that a local application (oral, aerogenic) prevent the animals from a lethal bacterial (S. pneumoniae) or viral (A/PR/8/34) infection. In first clinical trials a good compatibility of the drug was demonstrated.
Luther
P
P
Abteilung Immunologie des Forschungsinstitutes für Lungenkrankheiten und Tuberkulose, Berlin-Buch/DDR.
Brachmann
I
I
Werchan
D
D
Wittig
C
C
Tischner
H
H
D000281:Administration, Intranasal; D000284:Administration, Oral; D000328:Adult; D000818:Animals; D001419:Bacteria / Q000276:immunology; D001424:Bacterial Infections / Q000276:immunology / Q000517:prevention & control*; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D012141:Respiratory Tract Infections / Q000276:immunology / Q000517:prevention & control*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology
D001428:Bacterial Vaccines; D015164:Vaccines, Inactivated
Orale Applikation von "Infectvac" zur Prophylaxe von akuten respiratorische Infektionen (ARI).